Crenezumab

Crenezumab is a humanized IgG4 monoclonal antibody developed by Roche and Genentech that specifically targets [amyloid-beta](/proteins/amyloid-beta) (Aβ) oligomers and protofibrils for the treatment of [Alzheimer's disease](/diseases/alzheimers-disease). Unlike other anti-amyloid antibodies that primarily target Aβ plaques, crenezumab was designed to preferentially bind to soluble toxic oligomers, which are believed to be the most synaptotoxic species in Alzheimer's disease pathology.

Overview

Crenezumab represented a unique approach in the anti-amyloid antibody landscape by targeting Aβ oligomers rather than plaques.[@seyler_2023] This strategy was based on the growing recognition that soluble Aβ oligomers, not plaques, are the primary toxic species that drive synaptic dysfunction and cognitive decline in Alzheimer's disease.[@lacor_2007]

The antibody underwent extensive clinical development across multiple Phase 2 and Phase 3 trials, representing one of the most comprehensive development programs for an anti-oligomer approach.[@cummings_2024] While the clinical trials did not meet their primary endpoints, the program provided valuable insights into oligomer-targeted therapy and the importance of disease stage in Alzheimer's treatment.

Development timeline:

• 2007: Preclinical studies demonstrating oligomer targeting
• 2010: Phase 1 trials initiated
• 2012: Phase 2 (CREAD) initiated
• 2019: Phase 2 API AD trial results
• 2022: Phase 3 CREAD trials discontinued
• Status: Development discontinued following CREAD results

Crenezumab is a humanized IgG4 monoclonal antibody developed by Roche and Genentech that specifically targets [amyloid-beta](/proteins/amyloid-beta) (Aβ) oligomers and protofibrils for the treatment of [Alzheimer's disease](/diseases/alzheimers-disease). Unlike other anti-amyloid antibodies that primarily target Aβ plaques, crenezumab was designed to preferentially bind to soluble toxic oligomers, which are believed to be the most synaptotoxic species in Alzheimer's disease pathology.

Overview

Crenezumab represented a unique approach in the anti-amyloid antibody landscape by targeting Aβ oligomers rather than plaques.[@seyler_2023] This strategy was based on the growing recognition that soluble Aβ oligomers, not plaques, are the primary toxic species that drive synaptic dysfunction and cognitive decline in Alzheimer's disease.[@lacor_2007]

The antibody underwent extensive clinical development across multiple Phase 2 and Phase 3 trials, representing one of the most comprehensive development programs for an anti-oligomer approach.[@cummings_2024] While the clinical trials did not meet their primary endpoints, the program provided valuable insights into oligomer-targeted therapy and the importance of disease stage in Alzheimer's treatment.

Development timeline:

• 2007: Preclinical studies demonstrating oligomer targeting
• 2010: Phase 1 trials initiated
• 2012: Phase 2 (CREAD) initiated
• 2019: Phase 2 API AD trial results
• 2022: Phase 3 CREAD trials discontinued
• Status: Development discontinued following CREAD results

Mechanism of Action

Oligomer-Selective Binding

Crenezumab was engineered to have high affinity for Aβ oligomers while exhibiting relatively low affinity for Aβ plaques. This binding profile differentiated it from antibodies like [aducanumab](/entities/aduhelm) and [lecanemab](/entities/lecanemab) that target plaques with higher affinity.

Binding characteristics:

• Primary target: Aβ oligomers (soluble, toxic species)
• Secondary target: Aβ protofibrils (intermediate aggregates)
• Reduced binding: Aβ plaques (insoluble deposits)
• Minimal binding: Monomeric Aβ

Structural Basis of Specificity

Synaptic Protection Mechanism

The rationale for targeting oligomers was based on extensive preclinical research demonstrating that soluble Aβ oligomers are the primary synaptotoxic species:

Synaptic dysfunction mechanisms:

By neutralizing oligomers, crenezumab was designed to protect synapses from these toxic effects, potentially preserving cognitive function.

Comparison of Anti-Amyloid Mechanisms

| Antibody | Primary Target | Plaque Binding | ARIA Risk | Mechanism |
|----------|---------------|----------------|-----------|-----------|
| Crenezumab | Oligomers | Low | Low | Oligomer neutralization |
| Lecanemab | Protofibrils | Moderate | Moderate | Protofibril clearance |
| Aducanumab | Plaques | High | High | Plaque removal |
| Donanemab | Plaques | High | Moderate | Plaque removal |

Preclinical Development

In Vitro Studies

Preclinical characterization demonstrated crenezumab's oligomer-selective binding:

Key findings:

• Oligomer binding: High affinity for synthetic Aβ oligomers (Kd ~10⁻¹¹ M)
• Plaque binding: Low affinity for synthetic Aβ plaques
• Specificity: Minimal cross-reactivity with other amyloid proteins
• Epitope recognition: Binds to Aβ residues 1-16, spanning the N-terminal region

In Vivo Models

Transgenic mouse models:

• APP/PS1 mice: Reduced soluble Aβ levels, improved memory performance
• Tau transgenic models: Investigated combination with tau-targeting approaches
• Mechanism studies: Demonstrated Fc-mediated clearance through microglia

• Reduced hippocampal synaptic loss
• Improved performance on spatial memory tasks
• Reduced neuroinflammation markers

Clinical Development

Phase 1 Studies

First-in-Human Study (NCT00749216)

• Design: Single ascending dose, placebo-controlled
• Doses: 0.3, 1, 3, 10, 15 mg/kg
• Participants: 40 healthy volunteers, 24 patients with mild-to-moderate AD

• No dose-limiting toxicity up to 15 mg/kg
• Linear pharmacokinetics with half-life ~21 days
• Low incidence of ARIA (consistent with oligomer-targeting)
• Suggestion of biomarker engagement

Phase 1b (NCT01343966)

• Design: Multiple ascending dose in early AD patients
• Doses: 1, 3, 5, 10 mg/kg monthly for 6 months

• Dose-dependent reduction in CSF Aβ42
• Favorable safety profile
• Low ARIA incidence
• Biomarker changes supporting target engagement

Phase 2 Studies

CREAD Trial (NCT01998841)

The CREAD trial was the primary Phase 2 study evaluating crenezumab in early Alzheimer's disease:

| Parameter | Details |
|-----------|---------|
| Design | Randomized, double-blind, placebo-controlled |
| Patients | 431 with prodromal to mild AD |
| Treatment | 4.5 mg/kg or 15 mg/kg IV monthly |
| Primary endpoint | Change in CDR-SB at 2 years |
| Duration | 2 years |

Results:

• Did not meet primary endpoint (no significant clinical benefit)
• Trend toward benefit in patients with early disease
• More pronounced effect in patients with lower baseline amyloid
• Favorable safety profile with low ARIA rates

CREAD OLE (NCT02538510)

• Design: Open-label extension following CREAD
• Patients: CREAD completers (n=252)
• Treatment: 15 mg/kg monthly for 2 additional years

• Long-term safety consistent with parent study
• Exploratory analyses suggested benefit in very early disease
• Supported hypothesis that treatment must begin very early

API AD Trial (NCT01998841)

The Alzheimer's Prevention Initiative (API) AD trial tested crenezumab in cognitively healthy individuals at genetic risk for AD:

| Parameter | Details |
|-----------|---------|
| Population | Autosomal dominant AD mutation carriers |
| Age | Preclinical (20-60 years) |
| Treatment | 15 mg/kg IV monthly |
| Primary | Biomarker changes, cognitive preservation |

Results:

• Reduced amyloid accumulation vs. historical controls
• Reduced CSF neurofilament light chain (NfL) - neuronal injury marker
• No significant clinical benefit in this preclinical population
• Provided evidence of target engagement and disease modification

Phase 3 Trials

CREAD 1 and CREAD 2 (NCT03110057, NCT03110096)

In 2018, Roche initiated two identical Phase 3 trials to confirm the Phase 2 findings:

| Trial | Patients | Status |
|-------|----------|--------|
| CREAD 1 | 810 early AD | Terminated (futility) |
| CREAD 2 | 790 early AD | Terminated (futility) |

Reason for termination:
In 2019, Roche announced the discontinuation of both trials based on futility analysis, indicating that the trials were unlikely to meet their primary endpoint. The decision was based on pre-planned interim analysis showing insufficient clinical benefit.

Implications:

• Highlighted challenges of treating established Alzheimer's disease
• Reinforced importance of very early intervention
• Led to strategic shift toward combination approaches

Safety and Tolerability

Favorable Safety Profile

Crenezumab demonstrated one of the most favorable safety profiles among anti-amyloid antibodies:

| Adverse Event | Crenezumab (15 mg/kg) | Placebo |
|---------------|----------------------|---------|
| ARIA-E | 5% | 1% |
| ARIA-H | 3% | 1% |
| Injection-related reactions | 8% | 5% |
| Headache | 12% | 10% |
| Upper respiratory infection | 9% | 8% |

Comparison to Other Anti-Amyloid Antibodies

The low ARIA rate was attributed to crenezumab's reduced binding to vascular amyloid and plaques:

| Antibody | ARIA-E Rate | ARIA-H Rate |
|----------|-------------|-------------|
| Crenezumab | 5% | 3% |
| Lecanemab | 13% | 8% |
| Donanemab | 24% | 7% |
| Aducanumab | 35% | 19% |

Long-Term Safety

• No new safety signals in OLE studies
• Consistent with Phase 2 profile
• No剂量-limiting toxicity identified

Pharmacokinetics and Pharmacodynamics

Pharmacokinetic Parameters

| Parameter | Value |
|-----------|-------|
| Half-life | ~21 days |
| Cmax (15 mg/kg) | ~280 μg/mL |
| Volume of distribution | ~80 mL/kg |
| Clearance | ~3 mL/day/kg |

Biomarker Effects

• CSF Aβ42: Increased (interpreted as reduced brain deposition)
• CSF tau: No significant change (suggesting limited downstream effect)
• CSF neurofilament light: Reduced in API trial (neuronal protection signal)
• Amyloid PET: Modest reduction in API trial

Clinical Efficacy Analysis

Primary Endpoint Results

The CREAD Phase 2 and Phase 3 trials did not meet their primary endpoint of slowing cognitive decline on the Clinical Dementia Rating-Sum of Boxes (CDR-SB):

• CREAD Phase 2: Treatment effect not statistically significant
• CREAD Phase 3: Terminated for futility

Subgroup Analyses

Post-hoc analyses revealed potential benefit in specific populations:

Interpretation

The results suggested that:

Comparative Analysis

Against Other Anti-Amyloid Antibodies

| Feature | Crenezumab | Lecanemab | Donanemab | Aducanumab |
|---------|------------|-----------|-----------|------------|
| Target | Oligomers | Protofibrils | Plaques | Plaques |
| Target affinity | High (oligomer) | High (protofibril) | High (plaque) | High (plaque) |
| ARIA rate | Very low | Low-moderate | Moderate | High |
| Clinical benefit | Not significant | Significant | Significant | Modest |
| FDA status | Discontinued | Approved | Approved | Withdrawn |

Lessons from Comparison

Scientific Contributions

Despite discontinuation, the crenezumab program contributed significantly to the field:

Understanding Oligomer Biology

Clinical Trial Design Insights

Safety Profile

Post-Development Analysis

Why Crenezumab Did Not Show Clinical Benefit

Possible explanations:

Implications for Future Development

The crenezumab results informed subsequent approaches:

Roche's Alzheimer's Pipeline

Following crenezumab discontinuation, Roche continued advancing other Alzheimer's programs:

| Program | Mechanism | Stage |
|---------|-----------|-------|
| Bepranemab (RG6102) | Anti-tau antibody | Phase 2 |
| Anti-ABI-3 antibodies | Tau pathology | Preclinical |
| Small molecule tau aggregation inhibitors | Preclinical | Preclinical |
| Neuroimaging tracers | Diagnostic | Marketed |

Cross-Linking and Related Content

| Related Entity | Connection |
|---------------|------------|
| [Amyloid-Beta](/proteins/amyloid-beta) | Primary drug target |
| [Alzheimer's Disease](/diseases/alzheimers-disease) | Indication |
| [Amyloid PET](/entities/amyloid-pet) | Diagnostic imaging |
| [Lecanemab](/entities/lecanemab) | Alternative anti-amyloid |
| [Donanemab](/entities/donanemab) | Alternative anti-amyloid |
| [Aducanumab](/entities/aduhelm) | Related antibody |
| [Roche](/entities/roche) | Developer company |
| [Genentech](/entities/genentech) | Co-developer |
| [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade) | Mechanism hypothesis |
| [Microglia](/entities/microglia) | Effector cells |

External Links

• [ClinicalTrials.gov - Crenezumab](https://clinicaltrials.gov/search?cond=Alzheimer+Disease&intr=crenezumab)
• [Roche Pipeline](https://www.roche.com/)
• [PubMed - Crenezumab Publications](https://pubmed.ncbi.nlm.nih.gov/?term=crenezumab)

Allen Brain Atlas Resources

• [Allen Human Brain Atlas](https://human.brain-map.org/) — Brain gene expression data for amyloid pathology targets
• [Allen Cell Type Atlas](https://celltypes.brain-map.org/) — Single-cell expression data for microglia

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Crenezumab discovered through SciDEX knowledge graph analysis: